User requirements for quantitative radiological reports in multiple sclerosis - Takeaways - MDSpire

User requirements for quantitative radiological reports in multiple sclerosis

  • By

  • David R. van Nederpelt

  • Zoe C. Mendelsohn

  • Lonneke Bos

  • Rozemarijn M. Mattiesing

  • Olga Ciccarelli

  • Jaume Sastre-Garriga

  • Ferran Prados Carrasco

  • Joost P. A. Kuijer

  • Hugo Vrenken

  • Joep Killestein

  • Menno M. Schoonheim

  • Bastiaan Moraal

  • Tarek Yousry

  • Giuseppe Pontillo

  • Àlex Rovira

  • Eva M. M. Strijbis

  • Bas Jasperse

  • Frederik Barkhof

  • April 16, 2025

  • 0 min

Share

  • 1

    Multiple sclerosis (MS) is a chronic neurological condition that can lead to significant disability and requires effective monitoring and diagnosis.

  • 2

    Automated segmentation techniques in MRI have improved the analysis of MS-related lesions but are underutilized in clinical practice.

  • 3

    Quantitative radiological reports (QReports) provide valuable automated data for MS management but lack widespread clinical adoption.

  • 4

    A Delphi panel was used to identify user requirements for QReports, aiming to enhance their relevance and implementation in clinical settings.

  • 5

    The study involved multiple iterations of questionnaires to gather expert consensus on QReport features, ensuring alignment with clinician needs.

Original Source(s)

User requirements for quantitative radiological reports in multiple sclerosis

  • by David R. van Nederpelt, Zoe C. Mendelsohn, Lonneke Bos, Rozemarijn M. Mattiesing, Olga Ciccarelli, Jaume Sastre-Garriga, Ferran Prados Carrasco, Joost P. A. Kuijer, Hugo Vrenken, Joep Killestein, Menno M. Schoonheim, Bastiaan Moraal, Tarek Yousry, Giuseppe Pontillo, Àlex Rovira, Eva M. M. Strijbis, Bas Jasperse, Frederik Barkhof

  • April 16, 2025

Related Content

Multiple sclerosis as a biological and clinical continuum: from risk factors to the early stages of disease

Coffee, Tea Linked to Lower Dementia Risk

Caffeinated beverages were associated with modest cognitive benefits in long-term study

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.